[Translation] Multicenter, randomized, double-blind, placebo-controlled evaluation of recombinant fourteen-valent human papillomavirus (HPV) vaccines (6,11,16,18,31,33,35,39,45,51,52,56,58 , type 59) (insect cells) in a phase III clinical trial of protective efficacy, safety and immunogenicity in healthy females aged 18-45
与安慰剂比较,评价接种3剂HPV疫苗(SCT1000)在18-45周岁健康女性中预防HPV6,11,16,18,31,33,35,39,45,51,52,56,58,59型别相关病变的保护效力。
[Translation] To evaluate the protection against HPV6,11,16,18,31,33,35,39,45,51,52,56,58,59 of 3 doses of HPV vaccine (SCT1000) compared with placebo in healthy women aged 18-45 years Protective efficacy against type-associated lesions.